Canada: Food, Drugs, Healthcare, Life Sciences

Semaglutide, the blockbuster GLP-1 receptor agonist marketed under names like Ozempic® (type 2 diabetes) and Wegovy® (weight loss), has rapidly become one of the most consequential drugs in modern healthcare.

Geographical indications (GIs), such as Champagne, Cognac, and Parmigiano Reggiano, are designations used to identify products whose characteristics, reputation, or quality are fundamentally linked to their geographical origin.

On July 2, 2025, the Federal Court of Canada (the Court) dismissed an appeal by the University of British Columbia (UBC) of a decision of the Trademarks Opposition Board (the TMOB)...

Important amendments to the Exception Patient Measure came into effect on June 2, 2025. A summary of the key changes is provided below.

Join Heather Barnhouse, Partner in our Edmonton office, as she explores women in leadership and entrepreneurship, and the ecosystem that supports them.

On June 30, the Patented Medicine Prices Review Board (PMPRB) published new Guidelines for PMPRB Staff (the Guidelines) that will take effect on Jan. 1, 2026.

On May 29, 2025, the British Columbia legislature passed Bill 11, amending the Employment Standards Act. It prohibits most BC employers from requiring medical notes for short-term, health-related absences...

In Alberta Union of Provincial Employees v Alberta Health Services, 2025 ABKB 465 (AUPE v AHS), the Alberta Court of King's Bench upheld the Alberta Labour Relations Board's...

A recent Federal Court of Appeal decision about medical psilocybin use exemptions is a great illustration of the administrative law principle that a significant policy shift must be adequately explained.

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.